| PDCA循环在静脉药物配置中心提高抗肿瘤药物配置质量中的应用 |
| |
| 引用本文： | 李静,石庆平,彭德峰. PDCA循环在静脉药物配置中心提高抗肿瘤药物配置质量中的应用[J]. 中华全科医学, 2018, 16(12): 2095. DOI: 10.16766/j.cnki.issn.1674-4152.000571 |
| |
| 作者姓名： | 李静 石庆平 彭德峰 |
| |
| 作者单位： | 1. 蚌埠医学院第一附属医院静配中心, 安徽 蚌埠 233004; |
| |
| 基金项目： | 安徽省教育厅2014年度高等教育振兴计划人才项目[皖教秘人(2014)181号]；安徽高校自然科学研究项目(KJ2015B097by) |
| |
| 摘 要： | 目的 探讨PDCA管理循环在静脉药物配置中心(pharmacy intravenous admixture services,PIVAS)提高抗肿瘤药物配置质量中的应用效果,为提高抗肿瘤药物配置质量提供参考。 方法 选取2016年2月-2018年3月蚌埠医学院第一附属医院静配中心药师人员及护理人员30名为研究对象,分为PDCA循环实施前(2016年2月-2017年2月)和PDCA循环实施后(2017年3月-2018年3月)2个时间段。PDCA循环实施前予以常规药物配置质量管理,PDCA循环实施后采用PDCA循环进行药物配置质量管理,对比2组间抗肿瘤药物配置不合理的发生率及配置不合理类型的分布情况。 结果 实施前抗肿瘤药物配置不合理率为0.88%,实施后为0.51%,2组比较差异有统计学意义(P<0.05)。PDCA实施前后在溶剂选择、药物剂量、存在配伍禁忌、药物容器选择这4种类型的药物不合理配置上差异无统计学意义(均P>0.05);在溶剂剂量配置不合理及药物存放条件不合理中,实施后所占比例均明显低于实施前,且差异均具有统计学意义(P<0.05)。 结论 将PDCA循环管理用于静脉配置中心效果理想,能降低静脉配置中心抗肿瘤药物配置不合理的发生几率,减少抗肿瘤药物溶剂剂量配置不合理及药物存放条件不合理的发生率,有利于提高抗肿瘤药物的配置质量,值得应用于静脉配置中心抗肿瘤药物配置质量管理。
|
| 关 键 词： | PDCA循环 静脉配置中心 抗肿瘤药物 |
| 收稿时间： | 2018-05-07 |
Application of Plan-Do-Check-Act cycle in improving the quality of antitumor drugs intravenous admixture services |
| |
| Affiliation: | Drug Distribution Center, the First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, China |
| |
| Abstract: | Objective To explore the effect of Plan-Do-Check-Act (PDCA) circulation in improving the quality of anti-tumor drug configuration in pharmacy intravenous admixture services (PIVAS), and provide reference for improving the quality of anti-tumor drug configuration. Methods The pharmacists and nursing staff of the First Affiliated Hospital of Bengbu Medical College from February, 2016 to March, 2018 were enrolled into this study and assigned into the control group (February 2016-February 2017) and the study group (March 2017-March 2018) according to the time point. The control group was managed with the conventional drug allocation, while the study group with the PDCA cycle. The incidence and types of unreasonable anti-tumor drug allocation were compared between the two groups. Results The incidence of unreasonable anti-tumor drug allocation in the study group was 0.51% and in the control group was 0.88%, the difference was statistical significant (P<0.05). There was no significant difference between the study group and the control group in the unreasonable allocation of the selection of solvent, the dosage of drugs, the incompatibility of drugs and the selection of containers (P>0.05). The proportion of the unreasonable allocation solvent dose and drug storage conditions in the study group were both significantly lower than those of the control group, and the difference were statistically significant (P<0.05). Conclusion The PDCA cycle is an ideal management for PIAS, which can reduce the incidence of unreasonable anti-tumor drug configuration in the PIAS, including dose and storage conditions. It can promote the improvement of the configuration quality of anti-tumor drugs, and is worthy of application in the PIAS. |
| |
| Keywords: | |
|
| 点击此处可从《中华全科医学》浏览原始摘要信息 |
|
点击此处可从《中华全科医学》下载免费的PDF全文 |
|
